125 related articles for article (PubMed ID: 15107587)
1. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver.
Watanabe M; Kumai T; Matsumoto N; Tanaka M; Suzuki S; Satoh T; Kobayashi S
J Pharmacol Sci; 2004 Apr; 94(4):459-62. PubMed ID: 15107587
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
3. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression.
Sy SK; Ciaccia A; Li W; Roberts EA; Okey A; Kalow W; Tang BK
Eur J Clin Pharmacol; 2002 Aug; 58(5):357-65. PubMed ID: 12185560
[TBL] [Abstract][Full Text] [Related]
4. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver.
Sumida A; Kinoshita K; Fukuda T; Matsuda H; Yamamoto I; Inaba T; Azuma J
Biochem Biophys Res Commun; 1999 Aug; 262(2):499-503. PubMed ID: 10462503
[TBL] [Abstract][Full Text] [Related]
5. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Kamdem LK; Meineke I; Koch I; Zanger UM; Brockmöller J; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):71-7. PubMed ID: 15232676
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
7. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver.
Iwahori T; Matsuura T; Maehashi H; Sugo K; Saito M; Hosokawa M; Chiba K; Masaki T; Aizaki H; Ohkawa K; Suzuki T
Hepatology; 2003 Mar; 37(3):665-73. PubMed ID: 12601364
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
9. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.
Kolwankar D; Vuppalanchi R; Ethell B; Jones DR; Wrighton SA; Hall SD; Chalasani N
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):388-93. PubMed ID: 17368239
[TBL] [Abstract][Full Text] [Related]
10. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
11. 6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes.
Araya Z; Wikvall K
Biochim Biophys Acta; 1999 Apr; 1438(1):47-54. PubMed ID: 10216279
[TBL] [Abstract][Full Text] [Related]
12. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
13. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
14. Variability of CYP3A7 expression in human fetal liver.
Leeder JS; Gaedigk R; Marcucci KA; Gaedigk A; Vyhlidal CA; Schindel BP; Pearce RE
J Pharmacol Exp Ther; 2005 Aug; 314(2):626-35. PubMed ID: 15845858
[TBL] [Abstract][Full Text] [Related]
15. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
16. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
18. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
Jang GR; Wrighton SA; Benet LZ
Biochem Pharmacol; 1996 Sep; 52(5):753-61. PubMed ID: 8765473
[TBL] [Abstract][Full Text] [Related]
19. Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Xenobiotica; 2001 Oct; 31(10):713-23. PubMed ID: 11695850
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.
Canaparo R; Nordmark A; Finnström N; Lundgren S; Seidegård J; Jeppsson B; Edwards RJ; Boobis AR; Rane A
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):240-8. PubMed ID: 17371528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
